Skip to main content

Table 2 Incidence of adverse reactions caused by weekly irinotecan and capecitabine (N = 52)

From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Adverse reaction Grade I Grade II Grade III Grade IV
  Number (%) Number (%) Number (%) Number (%)
Hematologic toxicity
Leukopenia 12 (23.1) 14 (26.9) 5 (9.6) 0 (0)
Neutropenia 9 (17.3) 10 (19.2) 6 (11.5) 3 (5.8)
Febrile neutropenia 3 (5.8) 0 (0) 1 (1.9) 0 (0)
Thrombocytopenia 5 (9.6) 3 (5.8) 0 (0) 0 (0)
Anemia 7 (13.5) 13 (25) 1 (1.9) 0 (0)
Non-hematologic toxicity
Diarrhea 16 (30.8) 5 (9.6) 3 (5.8) 1 (1.9)
Nausea 13 (25.0) 7 (13.5) 2 (3.8) 0 (0)
Vomiting 7 (13.5) 11 (21.2) 2 (3.8) 0 (0)
Anorexia 11 (21.2) 3 (5.8) 0 (0) 0 (0)
Fatigue 11 (21.2) 8 (15.4) 1 (1.9) 0 (0)
Alopecia 5 (9.6) 0 (0) 0 (0) 0 (0)
Hand-foot syndrome 3 (5.8) 0 (0) 1 (1.9) 0 (0)
Oral ulceration 5 (9.6) 1 (0) 1 (1.9) 0 (0)
Venous thrombus 1 (1.9) 0 (0) 0 (0) 0 (0)
Pulmonary infection 1 (1.9) 1 (1.9) 0 (0) 0 (0)
Hyperbilirubinemia 2 (3.8) 0 (0) 0 (0) 0 (0)
Constipation 1 (1.9) 1 (1.9) 0 (0) 0 (0)
Elevated creatinine 1 (1.9) 0 (0) 0 (0) 0 (0)
Elevated blood glucose 1 (1.9) 1 (1.9) 0 (0) 0 (0)
Respiratory alkalosis 1 (1.9) 0 (0) 0 (0) 0 (0)
Pain 3 (5.8) 0 (0) 0 (0) 0 (0)
Hypophosphatemia 0 (0) 0 (0) 1 (1.9) 0 (0)
Hypomagnesemia 0 (0) 1 (1.9) 0 (0) 0 (0)
Hypokalemia 0 (0) 0 (0) 1 (1.9) 0 (0)
\